I sold out today. They are basically back to square one with having to redevelop it for the inhaled version, do animal testing etc, and then if they do want to continue the phase1 multi dose trial they will need to reformulate it again for intravenous use. They can't just keep upping the dose because that's expensive, and could be toxic to the liver and other organs, and is more likely to have unwanted side effects. Well, really it's probably worse than square 1 because now the easiest route of admission has been taken off the table.
Hopefully long term it comes good, and I think I will buy back in later down the track. At the moment I can see this losing more share price wise. I will buy back in at a lower price when things turn around again. Best of luck to everyone still holding.
1AD Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)